ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    INCAGN1876-101
Previous Study | Return to List | Next Study

An Open-Label, Dose-Escalation, Safety Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02697591
Recruitment Status : Recruiting
First Posted : March 3, 2016
Last Update Posted : March 26, 2018
Sponsor:
Information provided by (Responsible Party):
Incyte Corporation ( Incyte Biosciences International Sàrl )

Brief Summary:
This is an open-label, non-randomized Phase 1/2 safety study of INCAGN01876 in subjects with advanced or metastatic solid tumors that will be conducted in 2 parts. Part 1 will determine the pharmacologically active dose and/or maximum tolerated dose of INCAGN01876. Part 2 will further evaluate the recommended dose determined in Part 1 in subjects with select tumor types.

Condition or disease Intervention/treatment Phase
Advanced Malignancies Metastatic Cancer Drug: INCAGN01876 Phase 1 Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 146 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors
Actual Study Start Date : April 2016
Estimated Primary Completion Date : May 2018
Estimated Study Completion Date : August 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: INCAGN01876 Drug: INCAGN01876
Initial cohort dose of INCAGN01876 monotherapy at the protocol-defined starting dose, with subsequent cohort escalations based on protocol-specific criteria. The recommended dose will be taken forward into expansion cohorts.




Primary Outcome Measures :
  1. Safety and tolerability will be assessed by monitoring frequency, duration, and severity of adverse events (AEs) [ Time Frame: AEs assessed from screening through 60 days after end of treatment, up to 18 months ]

Secondary Outcome Measures :
  1. Maximum observed concentration (Cmax) of INCAGN01876 in serum will be summarized [ Time Frame: Protocol-defined timepoints in treatment Cycles 1-7, up to 4 months ]
  2. Area under the single-dose concentration-time curve (AUC0-t) of INCAGN01876 will be summarized [ Time Frame: Protocol-defined timepoints in treatment Cycles 1-7, up to 4 months ]
  3. Objective response rate (ORR) per RECIST and modified RECIST (mRECIST) [ Time Frame: Preliminary efficacy at baseline and every 8 weeks for the first 12 months and then every 12 weeks thereafter for duration of study participation, up to 18 months ]
  4. Duration of response per RECIST and modified RECIST (mRECIST) [ Time Frame: Preliminary efficacy at baseline and every 8 weeks for the first 12 months and then every 12 weeks thereafter for duration of study participation, up to 18 months ]
  5. Rate of disease control per RECIST and modified RECIST (mRECIST) [ Time Frame: Preliminary efficacy at baseline and every 8 weeks for the first 12 months and then every 12 weeks thereafter for duration of study participation, up to 18 months ]
  6. Progression free survival (PFS) per RECIST and modified RECIST (mRECIST) [ Time Frame: Preliminary efficacy at baseline and every 8 weeks for the first 12 months and then every 12 weeks thereafter for duration of study participation, up to 18 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Locally advanced or metastatic disease; locally advanced disease must not be amenable to resection with curative intent
  • Part 1: Subjects with advanced or metastatic solid tumors
  • Part 2: Subjects with advanced or metastatic adenocarcinoma of endometrium, melanoma, non-small cell lung cancer, and renal cell carcinoma
  • Subjects who have disease progression after treatment with available therapies that are known to confer clinical benefit, or who are intolerant to treatment, or subjects who refuse standard treatment
  • Presence of measureable disease based on RECIST v1.1
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1

Exclusion Criteria:

  • Laboratory and medical history parameters not within the protocol-defined range
  • Receipt of anticancer medications or investigational drugs within protocol-defined intervals before the first administration of study drug
  • Has not recovered to ≤ Grade 1 from toxic effects of prior therapy and/or complications from prior surgical intervention before starting therapy
  • Receipt of a live vaccine within 30 days of planned start of study therapy
  • Active autoimmune disease that required systemic treatment in the past 2 years

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02697591


Contacts
Contact: Incyte Corporation Call Center 1.855.463.3463

Locations
United States, California
The Angeles Clinic and Research Institute Recruiting
Los Angeles, California, United States, 90025
Contact: Study Coordinator    310-231-2115      
Principal Investigator: Dr. Hamid         
United States, Connecticut
Yale University Recruiting
New Haven, Connecticut, United States, 06511
Contact: Study Coordinator    203-737-1889      
Principal Investigator: Dr. LoRusso         
United States, Massachusetts
Beth Israel Deaconess Medical Center Recruiting
Boston, Massachusetts, United States, 02215
Contact: Study Coordinator    617-632-9280      
Principal Investigator: Dr. Hodi         
Dana Farber Cancer Institute Recruiting
Boston, Massachusetts, United States, 02215
Contact: Study Coordinator    617-632-6287      
Principal Investigator: Dr. Hodi         
United States, New York
MSK Westchester Recruiting
Harrison, New York, United States, 10604
Contact: Study Coordinator    646-888-4440      
Principal Investigator: Dr. Harding         
Memorial Sloan Kettering Cancer Center Recruiting
New York, New York, United States, 10065
Contact: Study Coordinator    646-888-4440      
Principal Investigator: Dr. Harding         
United States, Tennessee
Vanderbilt University Medical Center Recruiting
Nashville, Tennessee, United States, 37232
Contact: Study Coordinator    615-875-7143      
Principal Investigator: Dr. Cardin         
Sponsors and Collaborators
Incyte Biosciences International Sàrl
Investigators
Study Director: John Janik, MD Incyte Corporation

Responsible Party: Incyte Biosciences International Sàrl
ClinicalTrials.gov Identifier: NCT02697591     History of Changes
Other Study ID Numbers: INCAGN 1876-101
First Posted: March 3, 2016    Key Record Dates
Last Update Posted: March 26, 2018
Last Verified: March 2018

Keywords provided by Incyte Corporation ( Incyte Biosciences International Sàrl ):
Solid tumor
adenocarcinoma of the endometrium
melanoma, non-small cell lung cancer (NSCLC)
renal cell carcinoma (RCC)
glucocorticoid-induced tumor necrosis factor receptor (GITR)

Additional relevant MeSH terms:
Neoplasm Metastasis
Neoplastic Processes
Neoplasms
Pathologic Processes